What's new? Log in Free sign up

Filing search / Kineta, Inc. / "Training"

Search information

Kineta, Inc.

Companies

"Training"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

59 results

Newest first Best match first

KANT Kineta, Inc.

of treatment in relation to alternative treatments; the amount of upfront costs or training required for physicians to administer Kineta’s product … into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any

21 Mar 24

4:06pm

KANT Kineta, Inc.

of upfront costs or training required for physicians to administer Kineta’s product candidates; the availability of coverage, adequate reimbursement from … , recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate

31 Mar 23

4:05pm

KANT Kineta, Inc.

Kineta Completes Reverse Merger with Yumanity Therapeutics

of upfront costs or training required for physicians to administer Kineta’s product candidates; the availability of coverage, adequate reimbursement from … , recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate

KANT Kineta, Inc.

Kineta Completes Reverse Merger with Yumanity Therapeutics

staff training initiatives; (26) objective goals relating to projects, including project completion, timing and/or achievement of milestones, project

KANT Kineta, Inc.

Quarterly report

these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product … ; longer accounts receivable collection times; longer lead times for shipping; language barriers for technical training; reduced protection

14 Nov 22

8:44am

b6xc6j euijk17v71

Prospectus supplement

Registration of securities issued in business combination transactions (amended)

4 Nov 22

4:49pm

fse47jki0au7i xts5wu

Registration of securities issued in business combination transactions (amended)

24 Oct 22

9:14am

Registration of securities issued in business combination transactions (amended)

24 Oct 22

9:14am

Registration of securities issued in business combination transactions (amended)

3 Oct 22

4:54pm

lyzz16chz kvvrr

Registration of securities issued in business combination transactions (amended)

3 Oct 22

4:54pm

Registration of securities issued in business combination transactions

29 Aug 22

12:00am

8atd7admwxk1cjixz43x

Registration of securities issued in business combination transactions

29 Aug 22

12:00am

0e7f5croklohml0 ag

Quarterly report

4 Aug 22

5:12pm

Quarterly report

12 May 22

4:59pm

pw7q4lb2xl ao8ub

Definitive proxy

25 Apr 22

4:01pm

24 Mar 22

4:31pm

7fhdypwv3ddman6

Entry into a Material Definitive Agreement

Quarterly report

15 Nov 21

7:51am

vyb t5vvipkng380l

Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants

Prev
1
2
3
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.